A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Pfizer
Eli Lilly and Company
Eli Lilly and Company
Canadian Cancer Trials Group
Wake Forest University Health Sciences
City of Hope Medical Center
University of Pisa
Leaf Vertical Inc.
Masonic Cancer Center, University of Minnesota
Northwestern University
University of Miami
Altor BioScience
University of Southern California
National Institutes of Health Clinical Center (CC)